Browsing Tag
Travere Therapeutics
5 posts
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps. Read how launch execution, pricing and full approval risks shape the next phase.
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.
Travere Therapeutics stock soars 25% as FDA skips advisory panel for FSGS drug FILSPARI
Travere stock jumped 25% after the FDA waived an advisory panel for its FSGS drug. Find out why FILSPARI could transform the rare kidney disease market.
FILSPARI secures full European approval: A major breakthrough for IgA nephropathy patients
Find out how FILSPARI’s full EU approval marks a major step for IgA nephropathy treatment and strengthens CSL Vifor and Travere Therapeutics’ rare disease focus.
Primary IgA nephropathy : FDA grants full approval to Travere Therapeutics’ Filspari
In a groundbreaking move, the US Food and Drug Administration (FDA) has granted full approval to Travere Therapeutics’…